Dr. Emil Mitter Kheterpal, MD

Dr. Kheterpal practices at The Bryn Mawr Urology Group in Rosemont, Pennsylvania.

Dr. Kheterpal's NPI, 1437369691, was assigned on May 23, 2007. Dr. Kheterpal graduated from Boston University School of Medicine in 2006. Dr. Kheterpal holds New York license 262361.

Dr. Kheterpal's primary practice is The Bryn Mawr Urology Group, at 919 Conestoga Road, Rosemont, PA 19010. The practice phone is (610) 525-6580. Dr. Kheterpal also practices at Academic Urology of PA, LLC, 2 Industrial Blvd, Paoli, PA 19301.

Dr. Kheterpal's primary practice is The Bryn Mawr Urology Group in Rosemont, Pennsylvania. Dr. Kheterpal is also affiliated with Duke University Hospital. The medical group on file is MidLantic Urology. Dmand AI also links Dr. Kheterpal to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kheterpal practices, 7 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Kheterpal's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Kheterpal is licensed in New York.

CMS data shows 4,884 Medicare services from Dr. Kheterpal across 24 procedure codes in 2024, for 692 Medicare patients. Medicare paid $196,382 for them. Every service was in an office.

CMS counts 692 Medicare patients who saw Dr. Kheterpal in 2024. The largest group is 65 to 74, with 341 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 3% are also on Medicaid. Their average risk score is 1.08, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kheterpal's median patient age at 71, with 13% women.

In 2024, Dr. Kheterpal wrote 2,967 Medicare Part D claims for 713 patients. 78% of them were for generic drugs. CMS names the drug for 2,770 of them, across 29 drugs with 11 or more claims each, at $3,474,579 in total drug cost. In 2023, CMS named 2,288 claims across 30 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Kheterpal for performance year 2024, reported as part of a group. Dr. Kheterpal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kheterpal as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 7 papers to Dr. Kheterpal, published from 2010 to 2015. 2013 was the busiest year, with 2. The most frequent topics are Neoplasm Grading and Urinary Bladder Neoplasms. Dr. Kheterpal's most frequent co-authors are Tyler Drew Haden, MD, Max Xiangtian Kong, MD and Jonathan Melamed, MD.

CMS Open Payments shows 399 general payments to Dr. Kheterpal from 54 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 72% of the total. Janssen Pharmaceuticals, Inc paid the most, $1,705.

Dr. Kheterpal graduated from Boston University School of Medicine in 2006.